Big pharmaceutical companies aren't at a crossroads so much as on the edge of a cliff. Thanks to a special provision in patent laws for drugs, companies lose intellectual property protection on pharmaceuticals after 20 years. After that, exclusive rights to the drugs fall into an abyss of competition from other companies making much cheaper generic versions. The point at which pharma companies lose exclusive rights to their drugs is called the patent cliff.
Federal health authorities on Friday approved Botox injections for the prevention of chronic migraines in adults, an advance experts described as "modest."
Allergan launched a marketing campaign to promote Botox for treating migraines, despite the fact that the FDA never gave it the green light. As punishment, the company received a bill for $600 million -- in the form of a fine and settlment -- from the Department of Justice.
Allergan is in a tough spot. It manufactures Botox, the blockbuster cosmetic product that's made with a diluted form of the most potent toxin on the planet. America's favorite smile-line smoother is safe to use, but a new paper in Scientific American suggests that the global market for the cosmetic treatment could indirectly create an international security threat -- one that Allergan should help sidestep.
The current economic downturn could give a nip and tuck to the $10 billion cosmetic surgery market, but simple consumer vanity may outweigh recession fears.
The death of Heath Ledger has drawn attention to the dangers of legal prescription drugs. CNN's Alina Cho has more.
The Food and Drug Administration may have caused pandemonium on Park Avenue and Rodeo Drive with its announcemenet late last week of a safety review of the famed cosmetic therapy, Botox. But on Wall Street at least a few financial analysts are advising investors to buy shares of Botox maker Allergan while they're cheap.
Allergan's stock took a dive on Friday after the Food and Drug Administration said its Botox had been linked to severe side-effects, including death in children being treated for cerebral palsy.
The wrinkle-remover market is growing, and Allergan's dermal filler Juvederm could be closing in on the industry leader, Restylane from Medicis.
Allergan, maker of Botox, dermal fillers and breast implants, beat first-quarter earnings expectations but failed to impress investors, as shares slipped 3 percent.
Seekers of eternal youth get collagen injections every few months, but the newly public company Artes Medical has a longer-lasting wrinkle remover in the works.
The FDA approved a new dermal filler from BioForm Medical, the company said, adding competition to a market currently dominated by Medicis and Allergan.
Stock prices for breast implant makers surged on Monday, following the FDA's decision on Friday to approve silicone implants, ending a 14-year ban for most women.
FDA approved silicone implants Friday, ending America's 14-year hiatus.
The market for painkillers for the shooting pain associated with cancer, diabetes and shingles is expected to soar over the next decade, driven by a largely untapped patient pool of millions of Americans.
The market for injectable wrinkle removers is about to get bigger, but it's also about to get crowded.
For the first time since 1992 - the year Bill Clinton was elected, John Gotti was convicted and Los Angeles spiraled into riots - silicone breast implants may once again be available in America.
The market for wrinkle-removing drugs is about to get more competitive, as Allergan prepares to launch a product in the U.S. that could threaten Medicis' dominance.
Allergan, a California biotech, is lucky enough to have a wide-open U.S. playing field free of immediate competitors for its blockbuster drug: the wrinkle remover Botox.
Business 2.0: The new skin tradeupdated: Sun Feb 05 2006 12:02:00
Last year, Cheri Isabell decided to do something about the years of sun worship and stress that were starting to show on her face.
Investors will be watching for a couple of key earnings statements and some movement in the trade deficit Tuesday morning, looking for either positive or negative signs that could help shake the market out of its weeks of stagnation.
It started in the late '90s as a rumor, then became a whisper, then a buzz. By last year every cosmetically correct woman on both coasts knew the secret. When you inject Botox--an obscure drug norm...
In a queasy, headachy economy like this one, it's easy to understand why investors would reach for the medicine chest. Pharmaceuticals stocks have shone for decades as growth stalwarts relatively u...
What does this crazy election mean to the drug sector?
For a do-good investor, John Rogers does much better than you'd think. His $168 million Ariel Growth fund shuns the stocks of polluters, tobacco companies, and outfits with insufficiently diverse w...
Corporate executives and directors generally buy their companies' shares only when they think the stocks are sharply undervalued. For this reason, analysts regard so-called insider buying (not to b...
Fortune: PRODUCTS TO WATCHupdated: Mon Dec 18 1989 00:01:00
TEDDY GRAHAMS One vanishing species the World Wildlife Federation need not get alarmed about: the billions of tiny teddy bear cookies disappearing from supermarket shelves across America. Nabisco's...
© 2013 Cable News Network. Turner Broadcasting System, Inc. All Rights Reserved.
|